Long-term tocainide therapy has been evaluated in 17 patients with ventricular arrhythmias. Ventricular tachycardia and/or fibrillation was recurrent and sustained in nine patients, and symptomatic but unsustained in three others. Five patients had frequent but only mildly symptomatic ventricular irritability. In all patients, arrhythmias could not be managed with quinidine, procainamide or propranolol. Tocainide doses ranged from 300 to 700 mg every 8 hours (mean steady-state plasma concentrations ranged from 5.75 to 12.18 gg/ml). Tocainide therapy was un-
TOCAINIDE IS A PRIMARY AMINE lidocaine analog which is effective for premature ventricular contraction suppression when given orally." 2 In short-term studies it is well absorbed, has a plasma half-life averaging 13. 5 hours" I and is well tolerated at effective plasma concentrations. There is a wide range of intersubject variability in the tocainide plasma concentration at which antiarrhythmic response and side effects occur. 4 To date all reported tocainide data have been derived from short-term therapy. This study reports our initial experiences using long-term tocainide administration to treat ventricular arrhythmias which could not be managed with other drugs. The study examines efficacy and side effects and the long-term stability of tocainide plasma concentrations. Additionally our findings using sequential ambulatory electrocardiographic (ECG) monitoring to determine drug efficacy have general implications for evaluating long-term antiarrhythmic drug efficacy.
Methods
Seventeen patients with ventricular arrhythmias are the subject of this report. Each had ventricular arrhythmias which could not be managed adequately with procainamide, propranolol, or quinidine, and each had been referred to Stanford University Hospital for control of these arrhythmias. Before initiating long-term therapy, all patients were made aware of the experimental status of tocainide and all gave written, informed consent. Previous arrhythmia history and antiarrhythmic drug trials were evaluated for each patient, and the type and previous frequency of ventricular arrhythmias was documented. Previous drug failures, based on either recurrence of arrhythmia or intolerable side effects, were reviewed.
Before tocainide administration, a therapeutic goal was defined for each patient. For those with frequent recurrent episodes of ventricular tachycardia or ventricular fibrillation resulting in severe symptoms or requiring frequent pharmacologic or electrical conversion, control of such symptomatic occurrences was established as the required evidence of drug effectiveness. For these patients reduction successful in eight patients; three died during therapy and five had no antiarrhythmic response. The data suggest that evaluation of longterm drug efficacy, using the criterion of reduction of asymptomatic arrhythmias, is best documented by multiple sequential ambulatory electrocardiographic recordings, both on and offthe drug. Tocainide controlled arrhythmias in nine patients (53%), with criteria of success being continued reduction of ectopic beats and/or control of symptomatic recurrences. Seven patients remain on therapy. Side effects generally have been minor and well-tolerated. of asymptomatic arrhythmias was not required for therapy to be considered successful. For patients with only infrequent episodes of major symptomatic arrhythmias and frequent asymptomatic ventricular ectopic activity, the defined goal for tocainide therapy was both a control of major symptomatic occurrences and asymptomatic ventricular irritability reduction determined by ambulatory ECG. For those whose ventricular irritability was totally asymptomatic or only caused mild palpitation, ambulatory ECG documentation of sustained suppression of ventricular irritability would be required. All ambulatory monitoring periods covered one 8-hour dose interval, during which the total number of premature ventricular ectopic beats was determined. Whenever ambulatory ECG monitoring played a role in judging the success or failure of therapy, the patient underwent one or two initial control recordings and similar 8-hour ambulatory ECG monitorings were then obtained frequently during outpatient therapy to document continuing arrhythmia suppression by tocainide. Each patient for whom suppression of asymptomatic arrhythmias was taken as a goal of therapy underwent drug withdrawals at four months and one year during continuous ECG monitoring in order to attempt to document the continuing efficacy of and need for tocainide. Tocainide therapy was considered successful if it achieved the predefined goals for a given individual patient.
Patients were followed at approximately monthly intervals during the first year and every two months thereafter. At each outpatient visit, hematologic, hepatic, and renal laboratory safety tests were obtained. In addition, blood was collected for determination of fluorescent antinuclear antibodies and for tocainide analysis, to determine patient compliance. On each visit, blood pressure was taken, the patient was questioned as to the occurrence of any side effects, and a physical examination was made. Patients underwent periodic ophthalmologic examinations during longterm therapy.
Initial tocainide doses were based on clinical response. In general, drug was administered on an 8-hour dosing regimen. As part of this study, a large number of blood samples were obtained in order to obtain pharmacokinetic data. After achieving steady-state plasma concentrations, each patient underwent blood sampling during one doseinterval to determine mean tocainide plasma concentration. To facilitate blood sampling, a small indwelling heparin lock was placed in a forearm vein. Blood samples were obtained at time 0 (predose), 0.5, 1.0, 1.5, 2.0, 3, 4, 6, and 8 hours after the usual dose was given. These samples were analyzed for tocainide plasma concentration using a previously described high pressure liquid chromatographic assay., The area under the plasma concentration time curve was determined for the dosing interval, using the trapezoidal rule.
Mean steady-state plasma concentration (Cp) was obtained by dividing the area under the plasma tocainide concentration time curve over the dose interval by the dose interval. Since the tocainide dose and dose interval varied slightly from patient to patient, all values of Cp were also expressed as mg/ml per mg/hr of tocainide taken.
In addition to the initial determination of mean steadystate plasma concentration over a dose interval and the randomly drawn blood samples obtained on each clinic visit, five patients underwent sequential evaluation of the longterm stability of plasma concentration. Each of these patients had, in addition to the initial mean steady-state plasma concentration determinations, a drug half-life determination over a 56-hour decay period. Each patient was rehospitalized in the Stanford General Clinic Research Center approximately one month after initiating therapy with tocainide. Plasma samples were obtained during one dose interval according to the time schedule listed above. In addition, during the attempts to withdraw these patients from chronic tocainide therapy at four months and one year, blood samples were obtained during the drug withdrawal period. Blood samples were obtained during the first eight hours of drug withdrawal on a dose schedule similar to that described above with additional samples drawn periodically for 56 hours. The mean steady-state plasma concentration during the first eight hours of drug withdrawal was determined, as well as the plasma half-life over 56 hours. Since different patients received different tocainide doses and individual patients underwent periodic dose and dose interval adjustments, the plasma concentrations were also expressed as ,ug/ml per mg/hr of tocainide taken.
Results

Patient Population
The 17 patients taking part in this study ranged in age from 25 to 68 years. Their clinical diagnoses are summarized in table 1. Eight patients had coronary artery disease. Six of these eight patients had experienced a total of nine well-documented myocardial infarctions prior to tocainide therapy. Three patients had undergone previous coronary artery bypass grafting, and one had undergone left ventricular aneurysmectomy. Three patients had mitral valve prolapse, three had apparently normal hearts except for the ventricular arrhythmias, two had previous aortic valve replacements for aortic stenosis, and one had a severe cardiomyopathy. Seven patients had previous episodes of congestive heart failure and five of these had only very marginal cardiac compensation at the time tocainide therapy was initiated and during subsequent therapy. These 17 patients took a variety of other cardiac and noncardiac medications, which are listed in table 1.
Arrhythmias
Nine patients had experienced previous recurrent sustained ventricular tachycardia or ventricular fibrillation. An additional three patients had had nonsustained, but severely symptomatic, paroxysmal ventricular tachycardia.
Each of the other five patients had had nonsustained and asymptomatic ventricular tachycardia and frequent premature ventricular beats documented on ambulatory ECG monitoring. Ten patients had had DC cardioversion on one or more occasions. After careful review of previous history, symptomatic occurrences of ventricular arrhythmias were considered to have occurred frequently enough in eight patients that control of symptomatic occurrences could be taken as the sole end point for successful therapy. An additional four patients had only infrequent symptomatic occurrences, but also had frequent asymptomatic ventricular irritability. For these four, prevention of symptomatic occurrences as well as documented sustained suppression of premature ventricular beats was required for tocainide therapy to be considered successful. Finally, for the five patients who had not experienced well-documented symptomatic arrhythmia occurrences, suppression of frequent asymptomatic ventricular irritability, present in all five, was required to consider tocainide therapy successful.
Previous Antiarrhythmic Therapy
Sixteen patients had previously been treated unsuccessfully with procainamide. One patient had refused to take medication every four hours for psychological reasons. Procainamide had not controlled arrhythmias in eight of the 16, and eight had experienced intolerable side effects. These side effects included systemic lupus erythematosus in four patients, nausea and vomiting in one patient, and severe postural hypotension in one patient. The average dose of procainamide given in these patients was 3.0 + 0.98 (SD) g/day. Two patients had contraindications to propranolol therapy. One of these had severe congestive heart failure and the other had steroid-dependent bronchial asthma. Of the remaining 15 patients, eight did not have their arrhythmias controlled with propranolol therapy and seven had intolerable side effects. These included severe fatigue in two patients, increasing congestive heart failure in two, worsening of chronic obstructive pulmonary disease in one, severe bradycardia in one, second degree A-V block in one, and severe diarrhea on two separate occasions in one patient. The average dose of propranolol was 163 ± 120 mg/day. All patients had received a trial with quinidine therapy, which caused intolerable side effects in nine patients and was ineffective in eight patients. These side effects included severe gastrointestinal disturbances in seven patients, quinidine purpura in one, and allergic reaction manifested by fever, rash and malaise in one patient. The average dose of quinidine sulphate used in these patients was 1.4 ± 0.4 g/day.
Tocainide Therapy
Total daily doses of tocainide ranged from 800 to 2100 mg daily (table 2) . For all patients except one, drug doses were given on an 8-hour schedule. Table 2 summarizes the mean plasma concentrations over one dosing interval determined after achieving steady-state therapy in these patients. These data were available for 15 of the 17 patients. Mean steadystate concentration over a dosing interval ranged from 5.75 to 12.18 ,g/ml. Normalized mean steady-state plasma concentration ranged from 0.097 to 0.204 ug/ml per mg/hr of tocainide taken. The random blood samples drawn throughout therapy in all patients receiving long-term treatment confirmed patient compliance and yielded plasma tocainide concentrations in the range of those determined during the initial blood sampling over one dose interval.
The pharmacokinetic data for the five patients who underwent sequential determinations of mean steady-state plasma concentration and plasma half-life are shown in table 3. Although there are some individual patient variations, it can be seen that there are no consistent long-term group trends for changes in either normalized mean steadystate plasma concentration or plasma half-life for periods up to one year.
Side Effects
Only three patients were completely free of side effects during the entire period of treatment with tocainide. A list of side effects observed and the number of patients having each is given in table 4. It should be emphasized that in almost every instance, these side effects were very minor and, for the most part, transient. In several instances they occurred only at high plasma concentrations during initial dosing and did not recur during subsequent oral therapy. Additionally, several patients avoided transient side effects caused by rapid drug absorption3 by taking the morning dose with food. Tocainide was continued in all three patients who developed a rash after approximately one month on tocainide therapy. This rash resolved completely in two patients and remained localized and under control with topical therapy in the third. Several of the side effects such as night sweats and sensations of hot and cold occurred only infrequently in the patients who experienced them and were not a limiting side effect.
Only one patient was forced to discontinue tocainide therapy because of possible side effects. This patient (no. 10) was a 57-year-old man who had had two previous episodes of idiopathic pericarditis prior to initiating any antiarrhythmic therapy. He developed severe systemic lupus erythematosus on procainamide and had antinuclear antibody titers which were positive at > 1:640 dilution at the initiation of tocainide therapy. His titers remained elevated throughout the course of therapy with tocainide. After three months on tocainide he developed a fever and had two recurrences of pericarditis with effusion. In addition, he had shown a fall in his hematocrit and hemoglobin from pre-tocainide levels. Tocainide therapy was discontinued in this patient despite good control of his arrhythmias because we could not exclude the possibility of a drug-induced exacerbation of what may have been a pre-existing collagen vascular disease.
Only patient 10 showed any abnormalities in the laboratory safety testing. No other patient showed a fall in blood counts, or changes in renal or hepatic function. Eleven patients underwent therapy with tocainide for more than two months. Of these, six had negative fluorescent antinuclear antibody titers at the time of entry, and all six remained negative throughout the course of tocainide therapy. Three patients had elevated titers on entry into the study and had a decrease in fluorescent antinuclear antibody titers of at least 2 tube dilutions during therapy with tocainide. One patient had unchanging low titers over the course of treatment with tocainide, and one (no. 10) demonstrated persistently elevated titers of > 1:640 throughout the tocainide therapy period. No patient on long-term therapy demonstrated any new abnormalities on ophthalmologic examination. No patient had a worsening of congestive heart failure or a significant or sustained increase in blood pressure due to tocainide therapy.
Antiarrhythmic Efficacy
Long-term tocainide therapy achieved the predefined antiarrhythmic goals in nine (53%) of the 17 patients. One of these was the patient who developed pericarditis; the drug was discontinued in this patient. Another patient (no. 9) showed a marked spontaneous decline in ventricular irritability during her four-month drug withdrawal and she has been subsequently maintained without tocainide ( fig. 1) . The other seven patients remain on long-term tocainide therapy for periods ranging from two to 27 months. Ventricular arrhythmias in one of these seven patients (no. 5) could not be controlled with quinidine or tocainide alone, but were controlled with a combination of quinidine and tocainide, and in another patient (no. 7) were markedly improved but not completely controlled with tocainide alone, and were ultimately completely controlled with tocainide in combination with disopyramide. Control of the recurrent major symptomatic episodes was obtained in each patient where this was a desired goal of therapy. Of the patients for whom sequential ambulatory ECG monitoring was used to docu- Pericarditis with fever and anemia 1 ment continued reduction in asymptomatic ventricular irritability as a criterion of drug success, one patient (no. 1) showed fewer ventricular ectopic beats on all recordings made during tocainide therapy, compared with all control recordings (initial controls plus drug withdrawals) made while not taking tocainide ( fig. 2 ). Two other patients (nos. 2 and 10) generally showed fewer ventricular ectopic beats while on tocainide therapy compared with recordings made while not taking tocainide. However, occasionally during tocainide therapy, recordings performed while on tocainide showed premature ventricular contraction frequencies in the range seen during the control recordings (figs. 3 and 4). In general we could not relate these data to either changes in clinical status or tocainide plasma concentration.
For five patients tocainide did not satisfy the goals of antiarrhythmic drug therapy. Two of these patients (nos. 11 and 12) showed no apparent initial reduction in premature ventricular ectopic beat activity on ambulatory ECG monitoring. One patient (no. 13) with recurrent sustained episodes of ventricular tachycardia had episodes of this arrhythmia while on tocainide therapy, and this medication was discontinued after I1/2 months. Two additional patients (nos. 8 and 14) were considered to be tocainide failures only after relatively prolonged periods of treatment with tocainide. Both patients showed apparent initial responses to tocainide when evaluated with ambulatory ECG monitoring. However, subsequent drug withdrawal control monitorings interspersed with monitorings while taking the drug revealed that these patients had marked spontaneous variation in total numbers of ventricular ectopic beats and it seemed possible that their apparent initial response to tocainide therapy was really only spontaneous variation in ventricular ectopy rather than true drug response (figs. 5 and 6). At the time ofherfour month withdrawal it was uncertain whether her low PVC levels during the preceding four months were due to tocainide effect or spontaneous decline. Several subsequent ambulatory ECGs showed from 15 to 50 PVCs/15 minutes suggesting drug effect during the preceding months. She never returned to her pre-drug arrhythmia level and has been followed off tocainide.
Three patients (nos. 15, 16, and 17) died while taking tocainide. One of these patients was a 68-year;old female with a severe cardiomyopathy who had been resuscitated from two previous out-of-hospital cardiac arrests. Prior to transfer to Stanford she had been in the hospital for several months and could not be weaned from a lidocaine drip without experiencing cardiac arrest. She was treated with tocainide doses of 400 mg every eight hours and was weaned from the lidocaine drip. On a combination of acebutolol and tocainide she showed a dramatic reduction in ventricular irritability and no symptomatic arrhythmias, and this response was sustained during her outpatient visits. After 3½/2 months of therapy, and despite an ambulatory ECG . Sequential ambulatory ECG data for patient 2. Format similar to figures I and 2. Note that the majority of ambulatory ECG recordings on tocainide showedfewer PVCs than those obtained off tocainide. However at two months and 10 months there were more PVCs on drug therapy than were noted on the 4 and 12 month control recordings done off tocainide.
monitoring the day previously which showed very little ventricular irritability, she experienced another episode of documented out-of-hospital ventricular fibrillation. She was initially resuscitated; however, she suffered severe brain damage and died of pneumonia several days later. Another patient was a 61-year-old white male who had had previous myocardial infarctions, coronary artery bypass surgery and left ventricular aneurysmectomy. He experienced extremely frequent ventricular irritability in the early postmyocardial infarction period and was treated with tocainide therapy. Despite marked reduction of arrhythmias on ambulatory ECG monitoring he died after one month on tocainide. Although there were no clinical symptoms, postmortem examination revealed an approximately 24-hour-old myocardial infarction. Terminal rhythm was documented as idioventricular. The third patient, a 54-year-old male with coronary artery disease, two previous myocardial infarctions, and borderline compensated congestive heart failure had had multiple hospitalizations for sustained ventricular tachycardia responding to cardioversion. After 11 days of tocainide therapy he experienced a cardiac arrest at home 120 -E I ,n 80 _ et T MONTHS FIGURE 4. Sequential ambulatory ECG data for patient 10. Format similar to figures 1-3. Note that the majority of recordings on tocainide showed fewer PVCs than those obtained off tocainide. However at three months while the patient was taking tocainide there were more PVCs than were noted on several of the control recordings.
due to documented ventricular fibrillation. His postmortem examination showed no evidence of recent necrosis.
Discussion
This report details our experience using tocainide to treat patients with ventricular arrhythmias which could not be managed with procainamide, propranolol, or quinidine.
Evaluation of antiarrhythmic drug efficacy in a patient population such as the one studied in this report must be interpreted with certain cautions. First, one must recognize that these patients are highly selected, the majority of whom were referred to Stanford specifically for therapy with 200 tocainide. In several instances, patients were clearly preselected who were known to be sensitive to lidocaine and might be expected to have a greater likelihood of responding to tocainide. In many instances the previously unsuccessful antiarrhythmic drug therapy was given before referral to Stanford. In most instances the previous drug side effects were well documented in medical records and substantiated by patient interviews. Documenting previous drug failures due to recurrences of arrhythmia was somewhat more difficult. Before being considered a drug failure, the patient was required to be taking what seemed to be a reasonable dose of the antiarrhythmic drug. Each patient was interviewed to be certain that he was taking the drug faithfully at the time the recurrence of arrhythmia occurred. In general, the lower doses of antiarrhythmic drugs were the ones associated with side effects, and the trials deemed ineffective because of poor arrhythmia control tended to have antiarrhythmic drug doses larger than the average doses. Although plasma concentrations were available in many instances on previously unsuccessful therapy, we recognize that for some patients we cannot entirely exclude the possibility that their arrhythmias were only apparently uncontrolled with standard antiarrhythmic therapy and the true reason for drug failure was inadequate plasma concentration of the drug. Finally, it must be recognized that evaluations of new antiarrhythmic drugs in this setting cannot be carried out in a controlled manner using placebos or blinding either the patient or the physicians caring for the patient as to the therapy given. Psychological impacts resulting from taking a new experimental form of therapy or other biases inherent in drug evaluations cannot be evaluated precisely in this type of study. Despite these limitations in the study, every effort was made to predefine specific goals of antiarrhythmic therapy and to follow patients carefully to document that these goals had been achieved.
One interesting observation resulting from this drug trial relates to the question of how one documents continuing drug efficacy. For 10 12 MONTHS FIGURE 6. Sequential ambulatory ECG data for patient 8. The initial control recording showed 58 PVCs/15 minutes and a recording on tocainide showed only 9 PVCs/15 minutes (85% decrease) thus suggesting drug effect. However, subsequent recordings on (closed circles, solid line) and off (open circles, dashed line) tocainide suggested this patient had a large amount ofspontaneous variation in PVC frequencies and that the initial apparent response was merely spontaneous variation in PVC frequencies mimicking antiarrhythmic drug response. The drug was discontinued after one year.
recurrences of arrhythmia, our experience in this tocainide study reconfirmed our previous experience6 that control of symptomatic recurrences of arrhythmia is a reasonable and logical end point for considering antiarrhythmic therapy a success. Documenting drug efficacy using suppression of asymptomatic ventricular irritability as a criterion proved to be more of a problem. The data obtained from ambulatory ECG monitorings documented the fact that, for some patients, continuing antiarrhythmic drug efficacy as measured by suppression of asymptomatic ventricular irritability can only be determined by multiple sequential recordings which include recordings both on and off the antiarrhythmic drug. The reason why multiple recordings over timeboth on and off drugare sometimes required to document antiarrhythmic drug efficacy in individual patients probably relates to the fact that in individual patients there may be large, spontaneous variations in ventricular ectopy which overlap with the range of premature ventricular contraction suppression that can be obtained with antiarrhythmic drugs.7 Thus, if one obtains a control ECG monitoring, initiates antiarrhythmic drug therapy, and then repeats ambulatory ECG monitoring and notes a 50 to 80% reduction in ventricular irritability, one may either be observing antiarrhythmic drug effect or spontaneous decline in ventricular irritability. Only by obtaining additional periodic recordings both on and off antiarrhythmic drug therapy can one be reasonably certain that one is observing antiarrhythmic drug effect rather than spontaneous variation in ventricular ectopy. Our data from several patients also suggest that even when almost all recordings made on drug therapy have fewer ventricular ectopic beats than all control recordings made off antiarrhythmic drug therapy, occasional recordings may show overlap.
These data emphasize the difficulties in documenting ongoing antiarrhythmic drug efficacy in individual patients using suppression of asymptomatic ventricular irritability as a criterion. It is apparent that documenting ongoing efficacy may require multiple recordings both on and off the drug. Using existing technology, such sequential monitorings are expensive and not feasible for managing large numbers of patients. Furthermore, for patients with severe arrhythmias there may be some risk associated with obtaining the periodic recordings after drug withdrawal. We do not know of a simple solution to this dilemma. Finally, one must recognize that there is at present no proven benefit to the patient from suppression of asymptomatic ventricular irritability.
In a recent study evaluating the hemodynamic effects of tocainide in patients with compensated left ventricular dysfunction, we noted small but significant rises in the pulmonary and systemic vascular resistances, and in aortic and pulmonary artery pressutres.8 In addition, there was a slight rise in left ventricular end-diastolic pressure without a change in overall cardiac index. In the present long-term study we did not note any apparent clinical detrimental hemodynamic effects of tocainide, despite the presence in seven patients of previous congestive heart failure that was relatively poorly controlled in five of the seven. There were no episodes of severe or sustained elevations in blood pressure in our patients during long-term therapy. Additionally, the drug was given safely to several patients who had evidence on their resting ECG of cardiac conduction defects. In no patients were any conduction changes noted during tocainide therapy.
Little is known about the long-term stability of plasma concentrations of antiarrhythmic drugs. Spontaneous or systematic increases or decreases in plasma drug concentrations during long-term therapy could lead to drug toxicity or ultimate drug ineffectiveness. Such changes in drug plasma concentration with time during chronic oral therapy could be due to hepatic enzyme induction or inhibition over time, changes in renal function, changes in disease state, or changes in response to environmental influences such as coadministration of other drugs. Wide intrasubject swings in plasma concentrations over time would make stable dosing difficult for drugs such as the antiarrhythmic drugs which have relatively narrow toxic-to-therapeutic ratios. Tocainide plasma concentrations remained reasonably stable over time for the patients studied. For patients in whom the dose was only marginally effective or borderline toxic such fluctuations as occurred in these patients could be clinically important. However, for many patients they appear to be of little consequence. It should be emphasized that our mean plasma concentration data were obtained in patients who did not exhibit obvious changes in hepatic or renal function. They were also hospitalized and therefore had drug administration times controlled for several doses preceding drug sampling. Thus, problems with drug compliance which may cause fluctuation in drug concentrations are eliminated from our pharmacokinetic data. In our patient population periodic blood samples drawn on an outpatient basis at the times of clinic visits were in the same range as values obtained during hospitalization, suggesting a good outpatient compliance.
Our finding of reasonably stable tocainide plasma concentrations over time must not be extrapolated to other patient populations or clinical settings. Tocainide plasma concentrations could be expected to fluctuate over time during chronic oral therapy, in response to changes in hepatic or renal function. Although our patients were taking a variety of drugs it is still possible that administration of other drugs could theoretically alter the plasma concentration of tocainide. Our data suggest that for stable cardiac patients in whom the above mentioned parameters are stable, tocainide plasma concentration remains relatively constant during chronic oral therapy.
A seemingly large number of patients in our study experienced side effects while on tocainide. We have included as side effects virtually any complaint the patient had which could not be otherwise explained. Reactions have been listed no matter how transient or infrequently they may have occurred. We emphasize that in most instances these side effects were infrequent or minor and were not a limiting factor in tocainide's successful use. In many of the patients, higher doses of tocainide could probably have been tolerated, and the upper limit of plasma concentration possible in patients remains unexplored. Additionally, most patients were treated with every-eight-hour dosing regimens in order to obtain the highest mean plasma concentration with the least fluctuations in peak and valley plasma concentrations, and still maintain a reasonable dosing interval which did not require middle of the night dosing. The possibility of every-twelve-hour administration in some patients was not explored.
Three patients died during tocainide therapy, including two who experienced ventricular fibrillation. Many of the patients in this study were critically ill, including several who could not be weaned from lidocaine infusions. The study of critically ill patients using newer antiarrhythmic drugs, of necessity, probably always will include some deaths.
Recently Fasola and co-workers9 reported their experience in evaluating aprindine in a group of patients with serious ventricular arrhythmias. In that study they noted five deaths in 23 patients evaluated. The ultimate role of tocainide for the therapy of cardiac arrhythmias is difficult to determine from a study of its administration to patients who are critically ill and/or have undergone previous extensive and unsuccessful antiarrhythmic therapy. Our data suggest, however, that tocainide has a place for treating severe arrhythmias not controllable with the antiarrhythmic drugs currently available in this country. At the time this study was begun, no patients had received long-term tocainide therapy, and we therefore reserved its long-term administration for this type of patient. Our data in these patients also suggest that long-term tocainide therapy is not associated with severe long-term side effects, and it should now be possible to determine its role as a firstline drug for treating ventricular arrhythmias. It must be recognized, however, that the total number of patients receiving long-term therapy with tocainide remains small. As has been noted for practolol,10 serious drug toxicity during long-term therapy may become apparent only after very large groups of patients have been treated for long periods of time with any new drug.
